5

A method for increasing apoptosis in tumor cells comprising contacting the tumor cells with.

- a) an effective amount of at least one antitumor chemotherapeutic agent and
- b) an effective amount of a ceramide, sequentially or concomitantly, wherein the apoptosis induced by the combination of the antitumor chemotherapeutic agent and the ceramide is greater than the apoptosis induced by contact of the tumor cells with either the antitumor chemotherapeutic agent alone or the ceramide alone, thereby increasing apoptosis in tumor cells.
- 2. A method of decreasing a size of a tumor comprising contacting the tumor with:
 - a) an effective amount of at least one antitumor chemotherapeutic agent and
 - b) an effective amount of a deramide, sequentially or concomitantly, wherein the induced decrease in size of the tumor by the combination of the antitumor chemotherapeutic agent and the ceramide is greater than the decrease in size of a tumor after contacting the tumor with either the antitumor chemotherapeutic agent alone or the ceramide alone, thereby decreasing the size of the tumor.
- 3. The method according to either claim 1 or 2, wherein the tumor cells are or the tumor is composed of cancer cells selected from the group consisting of leukemic cells, prostate cancer cells, pancreatic cancer cells and squamous cell carcinoma cells, breast carcinoma cells, melanoma cells, basal cell carcinoma cells, neuroblastoma cells, glioblastoma multiforme cells, myeloid leukemic cells, colon carcinoma cells, endometrial

10

25

30

35


25

30

35

5

10



- 4. A method according to either claim 1 or 2, wherein the tumor cells or the tumor are contacted first with at least one antitumor chemotherapeutic agent and subsequently contacted with the ceramide.
- 5. A method according to either claim 1 or 2 wherein the tumor cells or the tumor are present in a subject.
- 6. The method according to either claim 1 or 2, wherein the ceramide is selected from a C2-ceramide, C6-ceramide, C6-ceramide and a higher order ceramide.
- 7. The method according to either claim 1 or 2, wherein the antitumor chemotherapeutic agent is selected from the group consisting of paclitaxel, doxorubicin, cis-platin, cyclophosphamide, etoposide, vinorelbine, vinblastin, tamoxifen, colchinin, and 2-methoxyestradiol.
- 8. The method according to either claim 1 or 2, wherein the contacting with the antitumor chemotherapeutic agent is effected by cremophore delivery or liposome-mediated delivery and the contacting with the ceramide is effected by cremophore delivery, alcohol-mediated delivery or liposome-mediated delivery.
- 9. The method according to either claim 1 or 2, wherein the contacting with the antitumor chemotherapeutic agent and with the ceramide is effected by an administration route selected from the group consisting of intravenous,

10

5

25

30

35

- 10. A pharmaceutical composition comprising at least one antitumor chemotherapeutic agent in an amount effective to induce apoptosis of tumor cells and a ceramide in an amount effective to induce apoptosis of tumor cells and a pharmaceytically acceptable carrier.
- 11. method for treating dancer in a subject administering , comprising to the subject effective amount of at least one chemotherapeutic agent and an effective amount of at least one ceramide, sequentially concomitantly.
- The method according to claim 11, wherein at least 12. oneantitumor dhemotherapeutic agent subsequently at lea/st one ceramide is administered to the subject.
- 13. The method according to claim 11, wherein at least ceramide and subsequently at least antitumor chem ϕ therapeutic agent is administered to the subject.
- 14. method according to claim 11, wherein the antitumor otin hemotherapeutic agent is paclitaxel andthe ceramide is C6-ceramide.
- A meth ϕ d according to claim 11, 15. ceramide is a C2-ceramide, C6-ceramide, C8-ceramide or a higher order ceramide.